Every story in this section, newest first — page 42 of 373.
The Generation Essentials Group (NYSE:TGE) reported unaudited first-half 2026 net profit of US$22.8 million compared with US$2.1 million a year earlier, supported by business growth and the absence of a prior-year share-based payment expense.
Hormel Foods (NYSE:HRL) signed a definitive agreement to acquire Brakebush Brothers from the Brakebush family for approximately $1.055 billion, adding a processed chicken supplier to its Foodservice business.
Kenon Holdings (NYSE:KEN) agreed to acquire a 25% indirect equity interest in Vicinity District Energy, a U.S. district heating and cooling business, through a transaction valuing 100% of the company at $2.92 billion.
Sagimet Biosciences (NASDAQ:SGMT) announced 52-week results from license partner Ascletis’ Phase 3 open-label extension trial of denifanstat in moderate to severe acne, with treatment success reaching 56.7% among 240 patients.
Solidion Technology (NASDAQ:STI) announced its intent to pursue an all-cash acquisition of Flux Power Holdings (NASDAQ:FLUX) through a non-binding proposal, with no definitive agreement currently executed.
Cal-Maine Foods (NASDAQ:CALM) reported a first-quarter fiscal 2027 net loss attributable to the company of $58.615 million, reversing a year-earlier profit as net sales declined 41.5% to $539.607 million.
Concentrix Corporation (NASDAQ:CNXC) shares declined 11.5% premarket to $22.02 after the technology and services company reported a third-quarter 2026 loss following a $1.05 billion non-cash goodwill impairment charge.
AbbVie (NYSE:ABBV) announced Phase 1 results for investigational ABBV-295, reporting adjusted mean weight reductions of up to 9.8% after 12 weeks of weekly dosing in a study involving 60 participants.
Yiren Digital (NASDAQ:YRD) reported a second-quarter 2026 net loss of RMB449.6 million, compared with net income of RMB357.5 million a year earlier, as revenue declined 46% year over year to RMB890 million.
Oil prices were largely steady on Wednesday after a sharp decline in the previous session, as recovering Middle East exports reduced some supply concerns linked to disruptions through the Strait of Hormuz.
Apollo (NYSE:APO) announced that its managed funds completed the acquisition of Nippon Sheet Glass, a company operating in architectural, automotive and solar glass markets, and launched a new management structure.
Takeda (NYSE:TAK) announced Phase 3 LATITUDE study results for investigational drug zasocitinib (TAK-279), reporting statistically significant improvements compared with deucravacitinib in adults with moderate-to-severe plaque psoriasis.
AbbVie (NYSE:ABBV) announced that it will present 60 dermatology research abstracts, including three late-breaking presentations, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, covering multiple immune-mediated skin diseases.
Amentum (NYSE:AMTM) has been selected by United Kingdom nuclear site operator Sellafield as preferred supplier for a Projects and Asset Care Execution (PACE) framework contract valued at up to £2.1 billion ($2.78 billion).
AbbVie (NYSE:ABBV) reported positive Phase 2 APEX Part B study results for zumilokibart, with all three tested dose regimens achieving the primary endpoint among 346 adults with moderate to severe atopic dermatitis.
Tesla (NASDAQ:TSLA) is preparing to release its third-quarter 2026 delivery figures, with investors watching closely for signs of demand momentum amid a more competitive electric vehicle market.
L3Harris Technologies (NYSE:LHX) announced that it received an undefinitized contract from Lockheed Martin valued at more than $6 billion, excluding escalations, over seven years to expand propulsion production for the Terminal High Altitude Area Defense (THAAD) missile defense system.
Oncolytics Biotech (NASDAQ:ONCY) reported published preclinical findings showing that pelareorep increased markers associated with immune activation in hepatocellular carcinoma (HCC), the most common form of liver cancer.
Cosmos Health (NASDAQ:COSM) reported record second-quarter 2026 revenue exceeding $15 million at its CosmoFarm pharmacy distribution subsidiary.
Carnival Corporation (NYSE:CCL) reported third-quarter 2026 financial results, with record revenue and stronger operating expectations for the full year.
Propanc Biopharma (NASDAQ:PPCB) reported fiscal 2026 financial results and provided an update on development plans for PRP, its investigational cancer therapy candidate.
Lite Strategy (NASDAQ:LITS) reported fiscal 2026 results for the year ended June 30, marking its first fiscal year operating under a Litecoin treasury strategy.
1-800-FLOWERS.COM (NASDAQ:FLWS) announced a definitive agreement to sell PersonalizationMall.com and Things Remembered to PlanetArt, LLC for approximately $45 million in cash.
Iovance Biotherapeutics (NASDAQ:IOVA) raised its full-year 2026 revenue guidance following stronger-than-expected demand for its commercial products, Amtagvi and Proleukin.
